We would love to hear your thoughts about our site and services, please take our survey here.
Heres a good read to possibly give a more realistic undestanding with an example as to where the price should be and not where its at. Its a good indicator as to when Phase 2 trials begin and the value associated with it and other stages with success of course.IMO the diversity of their portfolio has derisked the chances of failure and improved the chances of gaining FDA appoval along the way . So for eg Phase 1 trials has a 12% success rate of FDA approval and now they are about to start Phase 2 that carries a higher approval percentage and makes them more attractive to big Pharma with less risks.
Looks to me at the moment its just about manipulating the price whilst they try to hide the real success.
https://www.baybridgebio.com/drug_valuation.html
Just in case no one hasn’t seen it ffs :-)
Yes of course they have treatments for other illnesses other than covid however the concerns are there
https://www.ft.com/content/f54bf71b-87be-4290-9c95-4d110eec7a90
Whilst we continue to suffer with the constant downward trend , now there's the argument growing with Joe Biden and EU backing about a possible vaccine patent waiver that's affecting and angering many Big Pharma companies. Even though Tiziana are producing a covid treatment then surely if this patent waiver argument is successful then surely there's a risk that this could create a similar argument and demand that covid treatment producers may have to also waiver their patents too ? Maybe that's what's contributed to the recent fall?
The RNS shows that unexpected good news can come from any part of the world at anytime and maybe now attracting more international investors. We just need to break the chain of anticipating how the news will play out in the US and restore some investor confidence.
https://biznewspost.com/market/stocks/is-the-hype-over-for-cellular-goods-shares-the-motley-fool-uk/
I agree Tiziana has a lot more in its pipeline than just relying on the development of a covid treatment compared to Sorrento Therapeutic's pipeline for eg that looks heavily dependant and more relating to the post.
As for reference into the spiking last July there was a Bloomberg interview on whether confusion between Tesla contributed towards that of which GC rebuked that however he does give an explanation for the uprise in investments into biotech companies.
https://www.youtube.com/watch?v=RHD8BsPMlMA
As for this weeks fireside chat and the redchip release imo I wouldn't be surprised if the reason behind them was to reiterate their pipeline position as they knew about the forthcoming Bloomberg post but in some way I think its still good exposure being highlighted alongside Gilead who are a far bigger company and could generate far greater long term interest.
Stocks That Soared on Covid Treatments Are Coming Back to Earth
(Bloomberg)
-- Covid-19 case numbers are soaring and health authorities are getting increasingly worried about coronavirus variants, yet investors are growing less optimistic about many of the companies that are trying to develop treatments for the infection.
Many of the stocks that skyrocketed in 2020 -- including Tiziana Life Sciences Plc and Sorrento Therapeutics Inc. -- have fallen from their highs amid mounting expectations that the pandemic can be suppressed through vaccination. At the same time, some biotechs such as France’s Abivax SA have abandoned trials for drugs to fight infection with the coronavirus.
“If share prices of these companies implicitly assume that many, many people will be treated every year then they’re clearly overvalued,” said Adam Barker, an analyst at Shore Capital.
To be sure, the surge in coronavirus cases in countries such as India shows that treatments will still be needed as new strains of the disease emerge that can escape first-generation immunity. It’s just turning out to be harder to develop effective drugs than the most optimistic investors expected.
There are hundreds of drugs in development for Covid-19. Ten have been approved for emergency use by the U.S. Food & Drug Administration and only one, Gilead Sciences Inc.’s remdesivir antiviral, has won full approval.
That drug hasn’t been shown to reduce deaths from the virus, only to reduce the time needed to recover from it. A surge in sales of the product hasn’t helped the stock price: Gilead is up about 8% since winning regulatory backing, underperforming an index of health-care stocks in the U.S.
Here’s a roundup of some of the Covid treatment stocks and where they stand more than a year on from the onset of the pandemic.
Tiziana Life Sciences Plc: -68% from 2020 peak
Tiziana peaked in July when it sought a U.S. patent for its monoclonal antibody TZLS-501 in the treatment of Covid-19. The company launched its first clinical trial for the nasally administered treatment in November, with positive results reported at the start of February. It’s planning to begin larger trials on both outpatients and inpatients, said Howard Weiner, a scientific advisor for Tiziana. The shares have fallen 7.1% this year.
Please note that only information which is already in the public domain will be discussed.
its important to acknowledge this statement and understand that this was not incorporated into their RNS for no reason.Whatever that maybe seems to be protected and imo I think its important not to get into arguments with other private investors over the limited news presented to us. Institutional investors have a far different relationship so we also have to give caution to who there interview was really aimed at.
Provide updates/Please note that only information which is already in the public domain will be discussed. So will we get more information on what we already know or is it just another reiterating interview? Hopefully we may get another update RNS before this takes place ?
Accustem paragraph on Tiziana website under about us section
Tiziana Life Sciences completed the demerger of StemPrinter from the company on October 30th, 2020. It is now expected that the Accustem Shares will have a standard listing on the Official List and be admitted to trading on the London Stock Exchange. The Tiziana Shares will retain their LSE listing but a process is underway to seek admission to the standard segment of the Official List and trading on the London Stock Exchange. It is expected that Accustem Admission will occur during Q1, 2021.
The above paragraph is taken from the Tiziana website with the expectation of trading Accustem on the LSE so if this has changed then IMO I would expect that there would have been an RNS to confirm a significant change of direction. So the recent RNS of their intent to trade on the Nasdaq I would take as additional significant news and unless we are told any different then the only problem at the moment is the delay in the shares allocation and the LSE listing date.
https://www.griproom.com/fun/10-signs-your-stock-is-being-manipulated. Maybe you can see some similarities here. Considering where we are and the potential ahead it looks more like this stock is being manipulated be careful.
A team of scientists from the European Institute of Oncology in Milan conducted a head-to-head comparison of StemPrintER with Oncotype DX in collaboration with the Royal Marsden Hospital and Queen Mary University in London with favorable results showing superior performance of StemPrintER over Oncotype DX
A paragraph taken from Accustem site but im not sure when this comparison test was performed however that's the main driver for Accustem They may be a one trick pony but if these results are clarified as still standing then this should only give a stronger value baseline for StemprintER.
The Exact acquisition of Genomic Health ended costing them $72 per share and the Oncotype DX was one of the main assets of their portfolio so imo this should add a better consideration of value to Accustems IPO pricing .
Today is the last trading day for investors to cash in on their tax free allowance and the markets are closed tomorrow and Monday soI can't see anything exciting happening today but bring on post Tuesdays 6th a new tax new year and hopefully some strong upward price movement over the next couple of months
A lot of takeovers have been when small companies pipelines are in phase 2 trial stages and above with reduced risk .So yesterdays announcements could now be creating greater interest from Big Pharma.
I said yesterday that if there’s any significant news it would expect it to be before the Bloomberg interview and here you go . Great news now let’s see a long awaited bounce
Great news and now the phase 2 trials have been declared there a possible chance that big Pharma could start to get involved if they're not doing so already in the background.
Hopefully we may get another RNS before the interview if it’s anything significant .